Following its FDA approval in August, the first mRNA flu vaccine is now available for the 2026–2027 flu season, prompting questions as people try to find and receive it. Online, some people report difficulty locating the vaccine, determining whether insurance covers it, or understanding who is eligible. Adults 65 and older are asking how the new vaccine compares with high-dose or other flu vaccines.
People are also asking why they might choose an mRNA flu vaccine over other options, what side effects to expect, and whether the technology changes the vaccine’s effectiveness, duration of protection, or safety. Some users report stronger short-term reactions, while familiar false claims about mRNA vaccines, including DNA alteration, shedding, and cancer, are resurfacing.
Recommendation
Provide clear information about who is eligible for the mRNA flu vaccine, where it may be available, and how it compares with other flu vaccine options. Explain the evidence supporting its safety and effectiveness and what side effects people may expect. Emphasize that other flu vaccine options remain available, and help people understand which vaccines may be recommended based on age and other factors.
Reading links: Infodemiology Initiative
Communication resources: Get tips for communicating about flu vaccines in 2026-2027
